Inflammatory myopathies: clinical, diagnostic and therapeutic aspects
- PMID: 12661042
- DOI: 10.1002/mus.10313
Inflammatory myopathies: clinical, diagnostic and therapeutic aspects
Abstract
The three major forms of immune-mediated inflammatory myopathy are dermatomyositis (DM), polymyositis (PM), and inclusion-body myositis (IBM). They each have distinctive clinical and histopathologic features that allow the clinician to reach a specific diagnosis in most cases. Magnetic resonance imaging is sometimes helpful, particularly if the diagnosis of IBM is suspected but has not been formally evaluated. Myositis-specific antibodies are not helpful diagnostically but may be of prognostic value; most antibodies have low sensitivity. Muscle biopsy is mandatory to confirm the diagnosis of an inflammatory myopathy and to allow unusual varieties such as eosinophilic, granulomatous, and parasitic myositis, and macrophagic myofasciitis, to be recognized. The treatment of the inflammatory myopathies remains largely empirical and relies upon the use of corticosteroids, immunosuppressive agents, and intravenous immunoglobulin, all of which have nonselective effects on the immune system. Further controlled clinical trials are required to evaluate the relative efficacy of the available therapeutic modalities particularly in combinations, and of newer immunosuppressive agents (mycophenolate mofetil and tacrolimus) and cytokine-based therapies for the treatment of resistant cases of DM, PM, and IBM. Improved understanding of the molecular mechanisms of muscle injury in the inflammatory myopathies should lead to the development of more specific forms of immunotherapy for these conditions.
Similar articles
-
[Dysimmune and inflammatory myopathies].Rev Prat. 2008 Dec 31;58(20):2253-60. Rev Prat. 2008. PMID: 19209656 Review. French.
-
Therapeutic approaches in patients with inflammatory myopathies.Semin Neurol. 2003 Jun;23(2):199-206. doi: 10.1055/s-2003-41136. Semin Neurol. 2003. PMID: 12894385 Review.
-
Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy.Eur Cytokine Netw. 1999 Dec;10(4):471-8. Eur Cytokine Netw. 1999. PMID: 10586113 Review.
-
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.Ann Rheum Dis. 2008 Dec;67(12):1670-7. doi: 10.1136/ard.2007.077974. Epub 2008 Feb 13. Ann Rheum Dis. 2008. PMID: 18272672 Clinical Trial.
-
[Dermatomyositis and polymyositis: clinical aspects and treatment].Ann Med Interne (Paris). 2001 Nov;152(7):455-64. Ann Med Interne (Paris). 2001. PMID: 11965087 French.
Cited by
-
Exercise: an important component of treatment in the idiopathic inflammatory myopathies.Curr Rheumatol Rep. 2005 Apr;7(2):115-24. doi: 10.1007/s11926-005-0063-2. Curr Rheumatol Rep. 2005. PMID: 15760590 Review.
-
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):544-7. doi: 10.1136/jnnp.2005.074781. J Neurol Neurosurg Psychiatry. 2006. PMID: 16543541 Free PMC article.
-
Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population.Rheumatol Int. 2013 Apr;33(4):1059-64. doi: 10.1007/s00296-010-1662-4. Epub 2010 Dec 2. Rheumatol Int. 2013. PMID: 21125282
-
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows _target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23. Ann Rheum Dis. 2014. PMID: 23434567 Free PMC article. Clinical Trial.
-
Cytokine Therapies in Neurological Disease.Neurotherapeutics. 2016 Jul;13(3):555-61. doi: 10.1007/s13311-016-0455-1. Neurotherapeutics. 2016. PMID: 27388288 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
